Login to Your Account

Lycera Expands Partnership with Merck for Potential $600M

By Catherine Shaffer
Staff Writer

Tuesday, February 12, 2013

Lycera Corp. doubled its sweet 2011 deal with Merck and Co. Inc., of Whitehouse Station, N.J., in a new agreement designed to expand on the companies' prior relationship, which has centered on retinoic acid-related orphan receptor (ROR[gamma]t). Lycera will receive an undisclosed up-front payment and research funding, and could receive more than $300 million in milestone payments based on research, development, regulatory and commercial accomplishments, plus royalties on marketed products.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription